Press release
Primary Sclerosing Cholangitis Treatment Market Size in the 7MM is expected to grow a significant CAGR by 2032, estimates DelveInsight | Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therape
Primary Sclerosing Cholangitis Market
Key Takeaways from the Primary Sclerosing Cholangitis Market Report
• The increase in Primary Sclerosing Cholangitis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Primary Sclerosing Cholangitis Market is anticipated to witness growth at a considerable CAGR.
• The leading Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
• Promising Primary Sclerosing Cholangitis Therapies in the various stages of development include Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
Discover which therapies are expected to grab the Primary Sclerosing Cholangitis Market Share @ Primary Sclerosing Cholangitis Market Outlook- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation and scarring (fibrosis) of the bile ducts inside and outside the liver. Bile ducts are the tubes that carry bile (a digestive fluid produced by the liver) from the liver to the gallbladder and small intestine. In PSC, inflammation and scarring narrow and block the bile ducts, leading to problems with bile flow and causing damage to the liver over time.
Primary Sclerosing Cholangitis Epidemiology Insights
The epidemiology section of Primary Sclerosing Cholangitis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Primary Sclerosing Cholangitis Epidemiology trends @ Primary Sclerosing Cholangitis Epidemiological Insights- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Primary Sclerosing Cholangitis Drugs Market
The Primary Sclerosing Cholangitis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Primary Sclerosing Cholangitis signaling in Primary Sclerosing Cholangitis are likely to uncover new therapeutic targets and further expand treatment options for patients.
Primary Sclerosing Cholangitis Treatment Market Landscape
The Primary Sclerosing Cholangitis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Primary Sclerosing Cholangitis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Primary Sclerosing Cholangitis treatment guidelines, visit @ Primary Sclerosing Cholangitis Treatment Market Landscape- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Primary Sclerosing Cholangitis Market Outlook
The report's outlook on the Primary Sclerosing Cholangitis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Primary Sclerosing Cholangitis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Primary Sclerosing Cholangitis drug and late-stage pipeline therapy.
Primary Sclerosing Cholangitis Drugs Uptake
The drug chapter of the Primary Sclerosing Cholangitis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Primary Sclerosing Cholangitis.
Major Primary Sclerosing Cholangitis Companies
Several Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
Learn more about the FDA-approved drugs for Primary Sclerosing Cholangitis @ Drugs for Primary Sclerosing Cholangitis Treatment- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Primary Sclerosing Cholangitis Market Research Report
• Coverage- 7MM
• Primary Sclerosing Cholangitis Companies- Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
• Primary Sclerosing Cholangitis Pipeline Therapies- Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
• Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis Market Drivers and Barriers
• Primary Sclerosing Cholangitis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Primary Sclerosing Cholangitis Drugs in development @ Primary Sclerosing Cholangitis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Primary Sclerosing Cholangitis (PSC) Market Overview at a Glance
4. Executive Summary of Primary Sclerosing Cholangitis (PSC)
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Patient Journey
8. Emerging Therapies
10. Primary Sclerosing Cholangitis (PSC): Seven Major Markets + Nordic Countries Market Analysis
11. SWOT Analysis
12. Unmet Needs
13. KOL Views
14. Market Access and Reimbursement
15. Acronyms and Abbreviations
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
List of the Top Selling Market Research Reports in 2025
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
vulvar cancer market- https://www.delveinsight.com/report-store/vulvar-cancer-pipeline-insight
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
sepsis market- https://www.delveinsight.com/report-store/sepsis-market-insight
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
cart pipeline- https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Treatment Market Size in the 7MM is expected to grow a significant CAGR by 2032, estimates DelveInsight | Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therape here
News-ID: 3876592 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
